Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 526	$ 2,776
Accounts receivable	221	898
Prepaid expenses and other current assets	1,827	336
Total current assets	2,574	4,010
Property and equipment, net	525	594
TOTAL ASSETS	3,099	4,604
Current liabilities:
Accounts payable	5,370	3,208
Accrued expenses	2,173	3,670
Total current liabilities	7,543	6,878
Long-term debt	1,134
TOTAL LIABILITIES	8,677	6,878
Commitments and contingencies (Note 7)
Stockholders’ deficit:
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of June 30, 2020, and December 31, 2019; 17,023,824 and 14,887,999 shares issued as of June 30, 2020 and December 31, 2019, respectively; 17,022,972 and 14,887,147 shares outstanding as of June 30, 2020 and December 31, 2019, respectively	2	1
Additional paid-in capital	232,748	222,403
Treasury stock, at cost; 852 shares of common stock as of June 30, 2020 and December 31, 2019, respectively	(11)	(11)
Accumulated deficit	(262,280)	(248,630)
Total Vaccinex, Inc. stockholders’ deficit	(29,541)	(26,237)
Noncontrolling interests	23,963	23,963
TOTAL STOCKHOLDERS’ DEFICIT	(5,578)	(2,274)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 3,099	$ 4,604